NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.85 USD
-0.18 (-1.28%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $14.15 +0.30 (2.17%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Income Statements
Fiscal Year end for NeoGenomics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 592 | 510 | 484 | 444 | 409 |
Cost Of Goods | 347 | 322 | 297 | 259 | 212 |
Gross Profit | 245 | 188 | 187 | 186 | 197 |
Selling & Adminstrative & Depr. & Amort Expenses | 352 | 346 | 306 | 200 | 184 |
Income After Depreciation & Amortization | -108 | -158 | -119 | -14 | 13 |
Non-Operating Income | 18 | 0 | 109 | 7 | -6 |
Interest Expense | 7 | 2 | 5 | 7 | 4 |
Pretax Income | -97 | -159 | -15 | -14 | 4 |
Income Taxes | -9 | -15 | -7 | -18 | -4 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -88 | -144 | -8 | 4 | 8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -88 | -144 | -8 | 4 | 8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -32 | -85 | -63 | 26 | 44 |
Depreciation & Amortization (Cash Flow) | 75 | 72 | 56 | 40 | 31 |
Income After Depreciation & Amortization | -108 | -158 | -119 | -14 | 13 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 125.50 | 124.22 | 119.96 | 111.79 | 103.62 |
Diluted EPS Before Non-Recurring Items | -0.31 | -0.76 | -0.27 | 0.07 | 0.23 |
Diluted Net EPS (GAAP) | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 |
Fiscal Year end for NeoGenomics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 155.55 | 151.95 | 146.92 | 137.22 |
Cost Of Goods | NA | 87.96 | 89.64 | 87.03 | 82.41 |
Gross Profit | NA | 67.59 | 62.31 | 59.89 | 54.81 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 86.16 | 86.51 | 89.78 | 89.89 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -18.57 | -24.20 | -29.89 | -35.08 |
Non-Operating Income | NA | 0.12 | -0.10 | 0.73 | -0.11 |
Interest Expense | NA | 13.74 | -2.84 | -2.52 | -1.47 |
Pretax Income | NA | -15.29 | -21.45 | -26.64 | -33.72 |
Income Taxes | NA | -0.96 | -2.94 | -2.31 | -2.93 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -14.33 | -18.52 | -24.33 | -30.80 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -14.33 | -18.52 | -24.33 | -30.80 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 125.93 | 125.69 | 125.36 | 125.03 |
Diluted EPS Before Non-Recurring Items | NA | -0.02 | -0.06 | -0.09 | -0.13 |
Diluted Net EPS (GAAP) | NA | -0.11 | -0.15 | -0.19 | -0.25 |